Jubilant Life Sciences in a regulatory filing said it has been informed by the US Food and Drug Administration (USFDA) that inspection from December 10-18, 2018 at the Jubilant Generics Ltd API manufacturing facility, in Nanjangud, Mysore, has been classified as #39;Official Action Indicated#39; (OAI).USFDA classifies Jubilant Life#39;s Nanjangud facility as #39;Official Action Indicated#39;
Jubilant Life Sciences in a regulatory filing said it has been informed by the US Food and Drug Administration (USFDA) that inspection from December 10-18, 2018 at the Jubilant Generics Ltd API manufacturing facility, in Nanjangud, Mysore, has been classified as #39;Official Action Indicated#39; (OAI).
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment